Diatide gets $12 million from existing investors:
This article was originally published in Clinica
Diatide, a US company engaged in discovery and commercialisation of disease-specific medical imaging agents and therapeutics, has raised $11.8 million from three of its present shareholders in a private placement. Diatide has a strategic partnership with Nycomed, which has already taken up AcuTect thrombus imaging and P829 tumour imaging products. Diatide says there are five other products in stage II and III clinical trials.
You may also be interested in...
Brinavess Rejected By Advisory Cmte., Leaving US FDA To Mull Lifting Clinical Hold On Correvio's AFib Drug
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.